{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:05:07Z","timestamp":1760058307783,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: XTEND is the largest global, prospective, observational study of treatment-na\u00efve patients with neovascular age-related macular degeneration (nAMD) receiving 2 mg of intravitreal aflibercept (IVT-AFL) in routine clinical practice designed to examine the real-world effectiveness of IVT-AFL proactive treatment regimens. The outcomes from the Switzerland cohort are reported here. Methods: Patients aged \u226550 years were eligible if they planned to receive IVT-AFL 2 mg. After three initial monthly IVT-AFL injections, treatment intervals could be extended (4-week minimum treatment interval). Visual and anatomic outcomes, treatment exposure, and safety were assessed. Statistics were descriptive. Results: Fifty-one patients were treated. At baseline, the mean \u00b1 standard deviation (SD) best-corrected visual acuity (BCVA) was 64.9 \u00b1 17.9 letters, and central subfield thickness (CST) was 402 \u00b1 106 \u00b5m. At month (M) 12 and M24, the mean (95% confidence interval [CI]) change from baseline in BCVA was +5.7 (1.9, 9.4) and +5.6 (1.3, 9.8) letters, respectively. In patients with a high baseline BCVA (\u226570 letters [n = 28; mean \u00b1 SD: 77.5 \u00b1 4.8 letters]), BCVA was maintained at \u226570 letters at M12 and M24 (mean change from baseline [range] +1.0 [\u221215.0, 11.0] and +1.1 [\u201310.0, 14.0], respectively). At M12 and M24, the mean (95% CI) change in CST was \u2212125 (\u2212161, \u221290) \u00b5m and \u2212127 (\u2212162, \u221293) \u00b5m, respectively. Patients received a mean \u00b1 SD of 9.5 \u00b1 3.2 and 13.7 \u00b1 6.0 injections by M12 and M24, respectively. No safety concerns were identified. Conclusions: In Swiss routine clinical practice, functional and anatomic improvements were achieved with IVT-AFL 2 mg proactive treatment in patients with nAMD over 24 months despite a relatively high baseline BCVA.<\/jats:p>","DOI":"10.3390\/jcm14072370","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:50:16Z","timestamp":1743389416000},"page":"2370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0310","authenticated-orcid":false,"given":"Katja","family":"Hatz","sequence":"first","affiliation":[{"name":"Vista Eye Clinic Binningen, Hauptstrasse 55, 4102 Binningen, Switzerland"},{"name":"Faculty of Medicine, University of Basel, 4056 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[{"name":"Swiss Visio Montchoisi, 1006 Lausanne, Switzerland"},{"name":"R\u00e9tinElys\u00e9e, Ophthalmology Center, 1006 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schmid","sequence":"additional","affiliation":[{"name":"Eye Clinic, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland"},{"name":"Faculty of Health Sciences and Medicine, University of Lucerne, 6000 Lucerne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-8933","authenticated-orcid":false,"given":"Christian","family":"Pr\u00fcnte","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Eye Clinic Basel, 4031 Basel, Switzerland"},{"name":"Institute of Molecular and Clinical Ophthalmology Basel (IOB), 4031 Basel, Switzerland"},{"name":"Vue. Eye Center, 2502 Biel\/Bienne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Department of Ophthalmology, University of Zurich, 8006 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6844-4243","authenticated-orcid":false,"given":"Tobias","family":"Machewitz","sequence":"additional","affiliation":[{"name":"Bayer AG, 10115 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Allmeier","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care, AG, 4002 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-442X","authenticated-orcid":false,"given":"Gabor Mark","family":"Somfai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Eye Department, Spross Research Institute, 8063 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_2","unstructured":"VisionAtlas (2023, October 14). Country Map & Estimates of Vision Loss. Available online: https:\/\/www.iapb.org\/learn\/vision-atlas\/magnitude-and-projections\/countries\/switzerland\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","article-title":"Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES study","volume":"41","author":"Mitchell","year":"2021","journal-title":"Retina"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies","volume":"121","author":"Kaiser","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: Results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamaophthalmol.2021.1660","article-title":"Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related Macular degeneration","volume":"139","author":"Okada","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clinthera.2022.01.012","article-title":"Real-world evidence for regulatory decision-making: Guidance from around the world","volume":"44","author":"Burns","year":"2022","journal-title":"Clin. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Daien, V., Eldem, B.M., Talks, J.S., Korobelnik, J.F., Mitchell, P., Finger, R.P., Sakamoto, T., Wong, T.Y., Evuarherhe, O., and Carter, G. (2019). Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy\u2014A systematic approach to identify and characterize data sources. BMC Ophthalmol., 19.","DOI":"10.1186\/s12886-019-1208-9"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","article-title":"Evolution of treatment paradigms in neovascular age-related macular degeneration: A review of real-world evidence","volume":"105","author":"Daien","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1932296819832661","article-title":"The new FDA Real-World Evidence Program to support development of drugs and biologics","volume":"14","author":"Klonoff","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Weber, M., Dominguez, M., Coscas, F., Faure, C., Baillif, S., Kodjikian, L., and Cohen, S.Y. (2020). Impact of intravitreal aflibercept dosing regimens in treatment-na\u00efve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW. BMC Ophthalmol., 20.","DOI":"10.1186\/s12886-020-01468-z"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e000377","DOI":"10.1136\/bmjophth-2019-000377","article-title":"Impact of intravitreal aflibercept dosing regimens in treatment-na\u00efve patients with neovascular age-related macular degeneration in routine clinical practice in France: Results from the RAINBOW study","volume":"5","author":"Weber","year":"2020","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000109","DOI":"10.1136\/bmjophth-2017-000109","article-title":"Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study","volume":"4","author":"Weber","year":"2019","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s00417-021-05073-8","article-title":"PERSEUS 24-month analysis: A prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration","volume":"259","author":"Eter","year":"2021","journal-title":"Graefe\u2019s Arch. Clinical Exp. Ophthalmol"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s00417-022-05679-6","article-title":"PERSEUS-IT 24-month analysis: A prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration","volume":"260","author":"Nicolo","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ebneter, A., Michels, S., Pruente, C., Imesch, P., Eilenberger, F., Oesch, S., Thomet-Hunziker, I.P., and Hatz, K. (2020). Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-76354-1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/RMHP.S80536","article-title":"Anti-VEGF treatment patterns and associated health care costs in Switzerland: Findings using real-world claims data","volume":"8","author":"Reich","year":"2015","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","article-title":"Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen","volume":"3","author":"Traine","year":"2019","journal-title":"Ophthalmol. Retina"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/bjophthalmol-2020-316514","article-title":"Aflibercept for age-related macular degeneration: 4-year outcomes of a \u2019treat-and-extend\u2019 regimen with exit-strategy","volume":"106","author":"Jaggi","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hoffmann, L., and Hatz, K. (2021). External limiting membrane disruption predicts long-term outcome in strict treat-and-extend regimen in neovascular age-related macular degeneration. Front. Med. (Lausanne), 8.","DOI":"10.3389\/fmed.2021.706084"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40123-023-00867-x","article-title":"XTEND: Two-year results from a global observational study investigating proactive dosing of intravitreal aflibercept in neovascular age-related macular degeneration","volume":"13","author":"Korobelnik","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"ref_26","unstructured":"Swissmedic (2025, January 23). Structured Drug Information EYLEA Inj L\u00f6s 2 mg\/0.05 mL Durchstfl. Available online: https:\/\/sai.refdata.ch\/detail\/9048."},{"key":"ref_27","unstructured":"European Medicines Agency (2023, October 14). Eylea (Aflibercept) Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eylea."},{"key":"ref_28","unstructured":"Vorstand der Swiss Vitreoretinal Group (2025, January 28). Stellungnahme der SVRG zur antiVEGF Behandlung unter der COVID-19 Pandemie. Available online: https:\/\/retina.ch\/aktuelles\/stellungnahme-der-svrg-zur-antivegf-behandlung-unter-der-covid-19-pandemie\/."},{"key":"ref_29","first-page":"311","article-title":"Prospective evaluation of visual acuity assessment: A comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis)","volume":"107","author":"Kaiser","year":"2009","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Korva-Gurung, I., Kubin, A.M., Ohtonen, P., and Hautala, N. (2023). Visual outcomes of anti-VEGF treatment on neovascular age-related macular degeneration: A real-world population-based cohort study. Pharmaceuticals, 16.","DOI":"10.20944\/preprints202306.0061.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00417-022-05900-6","article-title":"Final 4-year results of the RAINBOW real-world study: Intravitreal aflibercept dosing regimens in France in treatment-naive patients with neovascular age-related macular degeneration","volume":"261","author":"Cohen","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40123-022-00541-8","article-title":"Patients with neovascular age-related macular degeneration requiring intensive intravitreal aflibercept treatment: An ARIES post hoc analysis","volume":"11","author":"Wolf","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: A mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bailey, C., Chandran, M., Gale, R., Narendran, N., Talks, J., McGoey, H., Keshk, Z., Morgan-Warren, P., Allmeier, H., and Machewitz, T. (2024). 2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2\u2009mg in patients with nAMD in clinical practice: XTEND study UK cohort. Eye.","DOI":"10.1038\/s41433-024-03550-y"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/aos.14698","article-title":"A novel tool to assess the quality of RWE to guide the management of retinal disease","volume":"99","author":"Finger","year":"2021","journal-title":"Acta Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:39Z","timestamp":1760029539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14072370"],"URL":"https:\/\/doi.org\/10.3390\/jcm14072370","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}